Amylyx Pharmaceuticals (AMLX) Exchange Rate Effect (2021 - 2026)
Amylyx Pharmaceuticals' (AMLX) quarterly Exchange Rate Effect came in at -$111000.0 in Q1 2026, down 156.35% year-on-year from $197000.0 in Q1 2025, and down 194.07% quarter-over-quarter from $118000.0 in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Exchange Rate Effect (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Exchange Rate Effect history runs 6 years deep, the most recent figure standing at -$111000.0 for Q1 2026.
- On a quarterly basis, Exchange Rate Effect fell 156.35% year-over-year to -$111000.0 in Q1 2026; TTM through Mar 2026 was $766000.0, a 684.73% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 345.21% from the prior year.
- Exchange Rate Effect declined to -$111000.0 in Q1 2026 per AMLX's latest filing, from $118000.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $608000.0 in Q2 2025 and bottomed at -$525000.0 in Q4 2024.
- The 5-year median for Exchange Rate Effect is -$18000.0 (2023), against an average of $36470.6.
- Biggest YoY gain for Exchange Rate Effect was 5533.33% in 2022; the steepest drop was 18550.0% in 2022.
- Year by year, Exchange Rate Effect stood at $507000.0 in 2022, then sank by 53.25% to $237000.0 in 2023, then plunged by 321.52% to -$525000.0 in 2024, then soared by 122.48% to $118000.0 in 2025, then plunged by 194.07% to -$111000.0 in 2026.
- Per Business Quant, the three latest AMLX Exchange Rate Effect figures stand at -$111000.0 (Q1 2026), $118000.0 (Q4 2025), and $151000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -17.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 17.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.01 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -4.20 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -5.00 Mn |
| 10 | Amylyx Pharmaceuticals | 1.94 Bn | 1.94 Bn | - | -111,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -111,000.00 |
| Mar 31, 2026 | -111,000.00 |
| Dec 31, 2025 | 118,000.00 |
| Dec 31, 2025 | 118,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Jun 30, 2025 | 608,000.00 |
| Jun 30, 2025 | 608,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Dec 31, 2024 | -525,000.00 |
| Dec 31, 2024 | -525,000.00 |
| Sep 30, 2024 | 236,000.00 |
| Sep 30, 2024 | 236,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Mar 31, 2024 | -110,000.00 |
| Mar 31, 2024 | -110,000.00 |
| Dec 31, 2023 | 237,000.00 |
| Dec 31, 2023 | 237,000.00 |